HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration - PubMed (original) (raw)
HMGB1 as an autocrine stimulus in human T98G glioblastoma cells: role in cell growth and migration
Rosaria Bassi et al. J Neurooncol. 2008 Mar.
Abstract
HMGB1 (high mobility group box 1 protein) is a nuclear protein that can also act as an extracellular trigger of inflammation, proliferation and migration, mainly through RAGE (the receptor for advanced glycation end products); HMGB1-RAGE interactions have been found to be important in a number of cancers. We investigated whether HMGB1 is an autocrine factor in human glioma cells. Western blots showed HMGB1 and RAGE expression in human malignant glioma cell lines. HMGB1 induced a dose-dependent increase in cell proliferation, which was found to be RAGE-mediated and involved the MAPK/ERK pathway. Moreover, in a wounding model, it induced a significant increase in cell migration, and RAGE-dependent activation of Rac1 was crucial in giving the tumour cells a motile phenotype. The fact that blocking DNA replication with anti-mitotic agents did not reduce the distance migrated suggests the independence of the proliferative and migratory effects. We also found that glioma cells contain HMGB1 predominantly in the nucleus, and cannot secrete it constitutively or upon stimulation; however, necrotic glioma cells can release HMGB1 after it has translocated from the nucleus to cytosol. These findings provide the first evidence supporting the existence of HMGB1/RAGE signalling pathways in human glioblastoma cells, and suggest that HMGB1 may play an important role in the relationship between necrosis and malignancy in glioma tumours by acting as an autocrine factor that is capable of promoting the growth and migration of tumour cells.
Similar articles
- Involvement of RAGE in radiation-induced acquisition of malignant phenotypes in human glioblastoma cells.
Seki H, Kitabatake K, Tanuma SI, Tsukimoto M. Seki H, et al. Biochim Biophys Acta Gen Subj. 2024 Sep;1868(9):130650. doi: 10.1016/j.bbagen.2024.130650. Epub 2024 Jun 1. Biochim Biophys Acta Gen Subj. 2024. PMID: 38830560 - Receptor for advanced glycation end products (RAGE) partially mediates HMGB1-ERKs activation in clear cell renal cell carcinoma.
Lin L, Zhong K, Sun Z, Wu G, Ding G. Lin L, et al. J Cancer Res Clin Oncol. 2012 Jan;138(1):11-22. doi: 10.1007/s00432-011-1067-0. Epub 2011 Sep 24. J Cancer Res Clin Oncol. 2012. PMID: 21947243 - Clinical Implications of High-mobility Group Box-1 (HMGB1) and the Receptor for Advanced Glycation End-products (RAGE) in Cutaneous Malignancy: A Systematic Review.
Nguyen AH, Detty SQ, Agrawal DK. Nguyen AH, et al. Anticancer Res. 2017 Jan;37(1):1-7. doi: 10.21873/anticanres.11282. Anticancer Res. 2017. PMID: 28011467 Review. - Pivotal role of high-mobility group box 1 (HMGB1) signaling pathways in glioma development and progression.
Angelopoulou E, Piperi C, Adamopoulos C, Papavassiliou AG. Angelopoulou E, et al. J Mol Med (Berl). 2016 Aug;94(8):867-74. doi: 10.1007/s00109-016-1435-y. Epub 2016 Jun 4. J Mol Med (Berl). 2016. PMID: 27262996 Review.
Cited by
- HMGB1/RAGE axis in tumor development: unraveling its significance.
Fan A, Gao M, Tang X, Jiao M, Wang C, Wei Y, Gong Q, Zhong J. Fan A, et al. Front Oncol. 2024 Mar 1;14:1336191. doi: 10.3389/fonc.2024.1336191. eCollection 2024. Front Oncol. 2024. PMID: 38529373 Free PMC article. Review. - Flavonoids Regulate Redox-Responsive Transcription Factors in Glioblastoma and Microglia.
Joma N, Zhang I, Righetto GL, McKay L, Gran ER, Kakkar A, Maysinger D. Joma N, et al. Cells. 2023 Dec 12;12(24):2821. doi: 10.3390/cells12242821. Cells. 2023. PMID: 38132142 Free PMC article. - The Importance of M1-and M2-Polarized Macrophages in Glioma and as Potential Treatment Targets.
Ren J, Xu B, Ren J, Liu Z, Cai L, Zhang X, Wang W, Li S, Jin L, Ding L. Ren J, et al. Brain Sci. 2023 Aug 31;13(9):1269. doi: 10.3390/brainsci13091269. Brain Sci. 2023. PMID: 37759870 Free PMC article. Review. - Inhibition of DAMP actions in the tumoral microenvironment using lactoferrin-glycyrrhizin conjugate for glioblastoma therapy.
Kim HS, Park SC, Kim HJ, Lee DY. Kim HS, et al. Biomater Res. 2023 May 20;27(1):52. doi: 10.1186/s40824-023-00391-w. Biomater Res. 2023. PMID: 37210579 Free PMC article. - Hypoxia-induced HMGB1 promotes glioma stem cells self-renewal and tumorigenicity via RAGE.
Ye C, Li H, Li Y, Zhang Y, Liu G, Mi H, Li H, Xiao Q, Niu L, Yu X. Ye C, et al. iScience. 2022 Aug 4;25(9):104872. doi: 10.1016/j.isci.2022.104872. eCollection 2022 Sep 16. iScience. 2022. PMID: 36034219 Free PMC article.
References
- Neurosurgery. 2002 Jul;51(1):2-12; discussion 12-3 - PubMed
- Adv Cancer Res. 2005;94:1-27 - PubMed
- Expert Rev Mol Diagn. 2006 Jul;6(4):613-26 - PubMed
- Cytokine Growth Factor Rev. 2006 Jun;17(3):189-201 - PubMed
- J Biol Chem. 2002 Jan 25;277(4):2790-7 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous